Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites.

International journal of oncology

Volumn 25, Issue 3, 2004, Pages 713-720

  Inoue, Masahiro ^a   Mukai, Mutsuko ^a   Hamanaka, Yukou ^a   Tatsuta, Masaharu ^a   Hiraoka, Masahiro ^a   Kizaka Kondoh, Shinae ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASP3 PROTEIN, RAT; CASPASE; CASPASE 3; DNA; DNA BINDING PROTEIN; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; HEME OXYGENASE; HEME OXYGENASE 1; HIF1A PROTEIN, RAT; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEAR PROTEIN; PRODRUG; TOP3 FUSION PROTEIN; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; ARTICLE; ASCITES; CELL HYPOXIA; CELL SURVIVAL; DRUG EFFECT; GENETICS; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; RAT; UPREGULATION;

ANIMALS; APOPTOSIS; ASCITES; CASPASE 3; CASPASES; CELL HYPOXIA; CELL SURVIVAL; DNA; DNA-BINDING PROTEINS; GLUCOSE TRANSPORTER TYPE 1; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; NUCLEAR PROTEINS; PRODRUGS; RATS; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12344276974     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.25.3.713     Document Type: Article

References (0)